Protocols

Stemline comes clean on patient death, but questions linger; Life sciences fund launches with €100M

Adam Feuerstein, Twitter

• Stemline $STML has been forced to admit that it received a report that one of the patients in its pivotal study of SL-401 for blastic plasmacytoid dendritic cell neoplasm (BPDCN) died after developing capillary leak syndrome, a condition that has already been linked to the drug. That admission followed a story from TheStreet’s Adam Feuerstein, who revealed the patient’s death for the first time. The big problem here is the timing. The death notice came on January 18, a day ahead of a $45 million offering, which failed to disclose the issue. The biotech’s shares have been ripped and analysts are wondering if the company can regain shareholders’ confidence.

• Ireland’s Seroba Life Sciences just closed its latest fund with €100 million. It’s already done one deal for Endotronix and Managing Partner Peter Sandys says a second is in the works.

• Braeburn Pharmaceuticals won’t be pursuing an IPO after all. The company, which has been marketing a tiny implant for treating opioid addiction, had been looking to sell 7.7 million shares at $18 to $21 each. New products are also in development.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->